Pre-vaccine period | Vaccine period | Pre-vaccine vs vaccine period | |||||||
---|---|---|---|---|---|---|---|---|---|
Average annual trend | 95% CI | p-value | Average annual trend | 95% CI | p-value | Summary rate ratio | 95% CI | p-value | |
Female – vulval/vaginal | |||||||||
15-24 years | 1.00 | 0.99 - 1.01 | 0.556 | 0.76 | 0.73 - 0.79 | <0.001 | 0.33 | 0.30 - 0.37 | <0.001 |
25-34 years | 0.98 | 0.97 - 0.99 | 0.001 | 0.93 | 0.90 - 0.97 | <0.001 | 0.60 | 0.54 - 0.66 | <0.001 |
35-44 years | 0.99 | 0.97 - 1.00 | 0.116 | 1.03 | 0.99 - 1.07 | 0.115 | 0.91 | 0.81 - 1.03 | 0.145 |
Male – penile | |||||||||
15-24 years | 1.1 | 1.04 - 1.1 | <0.001 | 0.86 | 0.80 - 0.93 | <0.001 | 0.76 | 0.62 - 0.96 | 0.022 |
25-34 years | 0.98 | 0.95 - 1.01 | 0.144 | 0.90 | 0.84 - 0.96 | 0.001 | 0.81 | 0.66 - 0.99 | 0.040 |
35-44 years | 0.97 | 0.93 - 1.01 | 0.125 | 0.93 | 0.84 - 1.03 | 0.161 | 0.70 | 0.51 - 0.95 | 0.024 |
Male – anal | |||||||||
15-24 years | 1.08 | 1.03 - 1.14 | 0.003 | 0.90 | 0.81 - 1.00 | 0.055 | 0.92 | 0.77 - 1.10 | 0.370 |
25-34 years | 0.97 | 0.94 - 1.01 | 0.143 | 0.95 | 0.87 - 1.04 | 0.241 | 0.69 | 0.59 - 0.79 | <0.001 |
35-44 years | 0.99 | 0.95 - 1.03 | 0.559 | 0.91 | 0.83 - 0.99 | 0.027 | 0.86 | 0.74 - 0.99 | 0.036 |